Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab.
Viral infection is an important cause of morbidity and mortality in the post-allograft period. Recently, a new therapeutic approach was developed in post-transplant lymphoproliferative disorder (PTLD) induced by Epstein-Barr virus (EBV): the anti-CD20 monoclonal antibody or rituximab. We performed a single-center study on the treatment effectiveness of rituximab in three EBV-induced PTLD and evaluated biologic data, such as T and B lymphocytes count, during PTLD development and treatment. Before PTLD treatment, blood cell profile showed a severe T lymphopenia with a progressive increase of CD8+ cells and B lymphopenia. Secondly, during treatment, there appeared a T response, as in primary EBV, and a regressive B lymphopenia.
Entz-Werle
Natacha
N
Service de Pédiatrie Onco-hématologie, CHRU Strasbourg, 67098 Strasbourg, France. Natacha.entz-werle@chru-strasbourg.fr
Cojean
Nadine
N
Barats
Audrey
A
Eyer
Didier
D
Munzer
Martine
M
Uring-Lambert
Béatrice
B
Falkenrodt
Annie
A
Babin
Annie
A
Lutz
Patrick
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes; D016026:Bone Marrow Transplantation; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes; D002648:Child; D020031:Epstein-Barr Virus Infections / Q000097:blood*; D005260:Female; D006801:Humans; D007223:Infant; D018655:Lymphocyte Count; D008232:Lymphoproliferative Disorders / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy* / Q000276:immunology*; D000069283:Rituximab; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab